Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
| ▸ | MMP12 | P39900 | 1/20 | 0.35 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | CHRNB2 | P17787 | 5/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.34 |
| ▸ | CHRNA2 | Q15822 | 3/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | APEX1 | P27695 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8114656 | 0.93 | KCNH2 (0.47) | KCNH2FFAR1FFAR4MMP2MMP12 | |
| SCHEMBL8122540 | 0.93 | KCNH2 (0.47) | KCNH2FFAR1FFAR4MMP2MMP12 | |
| SCHEMBL8122306 | 0.93 | KCNH2 (0.47) | KCNH2FFAR1FFAR4MMP2MMP12 | |
| SCHEMBL614112 | 0.89 | HRH3 (0.38) | KCNH2CHRNB2CHRNA4CYP1A2CYP3A4 | |
| SCHEMBL482776 | 0.82 | NPSR1 (0.39) | CHRNB2CHRNA4KDM4ELMNACYP1A2 | |
| SCHEMBL9295616 | 0.80 | FFAR1 (0.44) | KCNH2FFAR1FFAR4MMP2MMP12 | |
| SCHEMBL1979835 | 0.78 | HTR2A (0.35) | CHRNB2CHRNA4 | |
| SCHEMBL614578 | 0.77 | CYP1A2 (0.50) | KCNH2FFAR1FFAR4MMP2MMP12 | |
| Hydrochloric Acid SCHEMBL31144511 | 0.76 | BLM (0.52) | KCNH2FFAR1FFAR4MMP2MMP12 | |
| SCHEMBL6293461 | 0.75 | CHRNB2 (0.50) | CHRNB2CHRNA4LMNACYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160367639-A1 | MODIFICATION OF FEEDING BEHAVIOR | IMPERIAL INNOVATIONS LIMITED (GB) | 2016-12-22 | — | — | US | disclosed |
| EP-2329839-B1 | Modification of feeding behavior by GLP-1 and PYY | IMP INNOVATIONS LTD (GB) | 2015-09-16 | — | — | EP | disclosed |
| US-20150051140-A1 | MODIFICATION OF FEEDING BEHAVIOR | IMPERIAL INNOVATIONS (GB) | 2015-02-19 | — | — | US | disclosed |
| US-8217001-B2 | Modification of feeding behavior | IMPERIAL INNOVATIONS LIMITED | 2012-07-10 | — | — | US | disclosed |
| US-20120040893-A1 | MODIFICATION OF FEEDING BEHAVIOUR | COWLEY MICHAEL (AU) | 2012-02-16 | — | — | US | disclosed |
| US-8058233-B2 | adminsteration of Peptide YY and glucagons-like peptide-1( GLP-1) or agonists to a overweight subject, or having obesity related disorders, results in decreased food intake, caloric intake, appetite, and an alteration in energy metabolism | OREGON HEALTH AND SCIENCE UNIVERSITY (US) | 2011-11-15 | — | — | US | disclosed |
| EP-2329839-A1 | Modification of feeding behavior by GLP-1 and PYY | Imperial Innovations Limited (GB) | 2011-06-08 | — | — | EP | disclosed |
| US-7919329-B2 | Using proopiomelanocortin neuronal regulatory sequences to identify agents that affects caloric intake, energy expenditure, appetite or food intake; treating eating disorders and/or cachexia | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2011-04-05 | — | — | US | disclosed |
| US-20090209461-A1 | MODIFICATION OF FEEDING BEHAVIOR | IMPERIAL COLLEGE INNOVATIONS LTD. (GB) | 2009-08-20 | — | — | US | disclosed |
| EP-2050460-A1 | PYY and agonists thereof for modification of feeding behaviour | Imperial Innovations Limited (GB) | 2009-04-22 | — | — | EP | disclosed |
| US-20050015820-A1 | Assessment of neurons in the arcuate nucleus to screen for agents that modify feeding behavior | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-01-20 | — | — | US | disclosed |
| EP-1474163-A2 | MODIFICATION OF FEEDING BEHAVIOR | Imperial College Innovations Limited (GB) | 2004-11-10 | — | — | EP | disclosed |
| WO-2003026591-A9 | MODIFICATION OF FEEDING BEHAVIOR | IMP COLLEGE INNOVATIONS LTD (GB) | 2004-07-08 | — | — | WO | disclosed |
| EP-1137631-B1 | REVERSIBLE AQUEOUS pH SENSITIVE LIPIDIZING REAGENTS, COMPOSITIONS AND METHODS OF USE | UNIV SOUTHERN CALIFORNIA (US) | 2004-04-28 | — | — | EP | disclosed |
| WO-2003057235-A2 | MODIFICATION OF FEEDING BEHAVIOR | IMPERIAL COLLEGE INNOVATIONS LTD (GB) | 2003-07-17 | — | — | WO | disclosed |
| US-6590071-B1 | Increasing the delivery of hydrophilic amine containing compounds to the cell having a mucosal barrier, in which a compound of given formula penetrates the mucosal barrier of the cell; free amine is liberated by hydrolysis | UNIVERSITY OF SOUTHERN CALIFORNIA | 2003-07-08 | — | — | US | disclosed |
| WO-2003026591-A2 | MODIFICATION OF FEEDING BEHAVIOR | IMPERIAL COLLEGE INNOVATIONS LTD. (GB) | 2003-04-03 | — | — | WO | disclosed |
| WO-2003027637-A2 | ASSESSMENT OF NEURONS IN THE ARCUATE NUCLEUS TO SCREEN FOR AGENTS THAT MODIFY FEEDING BEHAVIOR | OREGON HEALTH AND SCIENCE UNIVERSITY (US) | 2003-04-03 | — | — | WO | disclosed |
| EP-1137631-A1 | REVERSIBLE AQUEOUS pH SENSITIVE LIPIDIZING REAGENTS, COMPOSITIONS AND METHODS OF USE | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2001-10-04 | — | — | EP | disclosed |
| WO-2000034236-A1 | REVERSIBLE AQUEOUS pH SENSITIVE LIPIDIZING REAGENTS, COMPOSITIONS AND METHODS OF USE | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2000-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209461-A1 | MODIFICATION OF FEEDING BEHAVIOR | NPY4R, NPY5R, NPY2R | KCNH2 4422/4885FFAR1 271/4885FFAR4 182/4885 |
| US-20150051140-A1 | MODIFICATION OF FEEDING BEHAVIOR | GLP1R, NPY4R, NPY1R | KCNH2 4416/4885FFAR1 198/4885FFAR4 212/4885 |
| US-20120040893-A1 | MODIFICATION OF FEEDING BEHAVIOUR | GLP1R, NPY4R, NPY1R | KCNH2 4346/4885FFAR1 165/4885FFAR4 174/4885 |
| US-20160367639-A1 | MODIFICATION OF FEEDING BEHAVIOR | GLP1R, NPY4R, NPY1R | KCNH2 4416/4885FFAR1 198/4885FFAR4 212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.